ClinicalTrials.gg
CompletedNCT00215371Updated Nov 11, 2010

Study in Patients With Asthma

A Phase 2 interventional study of Formoterol Fumarate in Asthma, sponsored by Dey. Completed at 2 sites in United States. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2010-11-11.

Sponsored by Dey (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
5 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 86 studies testing formoterol in Asthma — 2 open to participants now, 2 under way, 2 of them phase 3. formoterol · Asthma.

Enrollment
64th of 85
32 · median 100
Started
2002
with 5 others
Phase 2
17 of 86
none open now
Registered
2nd of 86
by date
Lead sponsor
4 of 86
Dey

Among the 86 studies testing formoterol in Asthma, this one is the 64th largest by enrollment of the 85 interventional ones that give a count, is one of 6 that started in 2002, is one of 17 in phase 2, and was the 2nd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

2 of the 86 studies testing formoterol in Asthma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing formoterol in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control group.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Pediatric
  • Formoterol Fumarate
  • Foradil
04

Who can participate

Ages eligible
5 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Require the regular use of an inhaled beta-2-selective adrenergic agent.
  • No abnormalities on the medical history, physical examination, and clinical laboratory tests.

Exclusion criteria

Exclusion Criteria:

  • Active acute or chronic disorders of the respiratory system within one month prior to screening.
  • Smoking history within the past 12 months or greater than a lifetime 10 pack-year smoking history.
  • Debilitating systemic and/or life-threatening diseases.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
32 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Primary: The primary efficacy outcome is measure of lung function.

Secondary outcomes

  1. Secondary: Change in lung function will be examined as a secondary efficacy outcome, as well as vital signs, physical examination, adverse event reporting,etc.

07

Study locations

2 sites
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Medford, Oregon 97504, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2002, a primary completion of Oct 2002 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 22, 2005
Start
Jul 2002
Primary completionActual
Oct 2002
CompletionActual
Nov 2005
Last update
Nov 11, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00215371
Lead sponsor
Dey
First posted
Sep 22, 2005
Start date
Jul 2002
Primary completion
Oct 2002
Completion
Nov 2005
Last update
Nov 11, 2010
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Formoterol

Start the discussion